<DOC>
<DOCNO>EP-0611755</DOCNO> 
<TEXT>
<INVENTION-TITLE>
(Cyclohexyl)-alken compounds, process for their preparation and pharmaceutical compositions containing them
</INVENTION-TITLE>
<CLASSIFICATIONS>C07C5772	C07C3300	A61K3112	C07C69734	C07F700	C07C5900	C07C40312	A61K3119	A61P1100	A61P2900	C07C40300	A61K3121	C07C2940	C07C3500	A61K31185	C07C6900	C07C40310	C07C69708	A61K3112	A61P3708	C07C69732	A61P3700	A61P1300	C07C69757	C07F708	C07C5954	A61P2900	C07C40320	C07C40318	C07D29518	A61K31695	C07D29500	A61K31215	C07C69675	A61P1302	C07C3517	A61K31695	A61P1700	A61P1100	C07C5700	C07C40308	C07C23530	C07C3314	A61P1500	C07C2900	A61P1700	A61P1500	C07C23500	C07F718	</CLASSIFICATIONS>
<CLASSIFICATIONS-THIRD>C07C	C07C	A61K	C07C	C07F	C07C	C07C	A61K	A61P	A61P	C07C	A61K	C07C	C07C	A61K	C07C	C07C	C07C	A61K	A61P	C07C	A61P	A61P	C07C	C07F	C07C	A61P	C07C	C07C	C07D	A61K	C07D	A61K	C07C	A61P	C07C	A61K	A61P	A61P	C07C	C07C	C07C	C07C	A61P	C07C	A61P	A61P	C07C	C07F	</CLASSIFICATIONS-THIRD>
<CLASSIFICATIONS-FOURTH>C07C57	C07C33	A61K31	C07C69	C07F7	C07C59	C07C403	A61K31	A61P11	A61P29	C07C403	A61K31	C07C29	C07C35	A61K31	C07C69	C07C403	C07C69	A61K31	A61P37	C07C69	A61P37	A61P13	C07C69	C07F7	C07C59	A61P29	C07C403	C07C403	C07D295	A61K31	C07D295	A61K31	C07C69	A61P13	C07C35	A61K31	A61P17	A61P11	C07C57	C07C403	C07C235	C07C33	A61P15	C07C29	A61P17	A61P15	C07C235	C07F7	</CLASSIFICATIONS-FOURTH>
<ABSTRACT>
The invention relates to the compounds of formula: 
<
IMAGE
>
  in which R1, R2, R3, R4, R5 and B are as defined in the description, to their enantiomers and diastereoisomers, to their Z and E isomers and to their addition salts with a pharmaceutically acceptable acid or base. Medicaments.
</ABSTRACT>
<APPLICANTS>
</APPLICANTS>
<INVENTORS>
</INVENTORS>
<CLAIMS>
Compounds of formula (I): 

 
wherein: 


B represents an alkylene chain having from 1 to 8 
carbon atoms that is unsubstituted or substituted by 

1 or 2 alkyl radicals, 
R
1
 represents a hydrogen atom or a radical selected 
from hydroxy and, alkoxy, 
R
2
 represents a radical selected from:
 
-CH
2
-OH and 

 
wherein R
6
 represents 
a group selected from hydroxyl, alkoxy, and 


 
wherein R
10
 and R
11
 represent, each 
independently of the other, a hydrogen atom, an alkyl 

radical, or an aryl or arylalkyl group, the aryl or 
arylalkyl group being unsubstituted or substituted on 

the aryl ring by one or more radicals selected from 
halogen, alkyl, alkoxy and trifluoromethyl, or R
10
 and 
R
11
 form, together with the nitrogen atom carrying 
them, a heterocycle selected from pyrrolidine,  

 
piperidine, piperazine, morpholine and thiomorpholine; 
R
3
 represents a group of the formula: 

 
wherein: 
R
7
 represents a radical selected from hydroxy, alkoxy, 
and -O-R
A
 wherein R
A
 represents an acyl radical or a 
protecting group for the hydroxyl function, 
R
9
 represents a hydrogen atom or a radical selected 
from alkyl, aryl and arylalkyl, the aryl or arylalkyl 

group being unsubstituted or substituted on the aryl 
ring by one or more radicals selected from halogen, 

alkyl, alkoxy and trifluoromethyl, 
or R
7
 and R
9
 form an oxo group, and 
R
8
 represents a linear or branched alkyl group having 
from 1 to 12 carbon atoms that is unsubstituted or 

substituted by one or more radicals selected from: 

hydroxyl, 
halogen, 
unsubstituted aryl, 
aryl that is substituted by one or more radicals 
selected from halogen, hydroxy, alkyl, alkoxy and 

trifluoromethyl, 
unsubstituted cycloalkyl, and 
cycloalkyl that is substituted by one or more 
radicals selected from halogen, alkyl, oxo and 

alkoxy, 
it being possible for R
8
 optionally to contain in  
 

its carbon skeleton: 

one or two hetero atoms selected from nitrogen, 
sulphur and oxygen, 
one or more unsaturated bonds, 
R
4
 and R
5
 represent, each independently of the 
other, a radical selected from hydrogen and alkyl, 

or R
4
 and R
5
 form, together with the cyclohexane 
carrying them, a 1,2,3,4-tetrahydronaphthalene or a 

perhydronaphthalene group,
 
it being understood that, unless otherwise specified, for 

the purpose of the description of formula (I): 
the terms "alkyl", "alkoxy" and "acyl" denote linear 
or branched groups having from 1 to 6 carbon atoms, 
the term "aryl" denotes a phenyl or naphthyl 
group, 
the term "unsaturated bond" denotes a double or 
triple bond, 
the term "cycloalkyl" denotes a group having from 
3 to 7 carbon atoms,
 
their enantiomers and diastereoisomers,
 
their Z and E isomers, and
 
the addition salts thereof with a pharmaceutically 

acceptable acid or base. 
Compounds according to claim 1 in which R
8
 
represents an unsubstituted linear or branched alkyl 

group having from 1 to 12 carbon atoms,
 
their enantiomers and diastereoisomers, their Z and E 

isomers, and the addition salts thereof with a  
 

pharmaceutically acceptable acid or base. 
Compounds according to claim 1 in which R
8
 
represents a linear or branched alkyl group having from 1 

to 12 carbon atoms that is substituted by an unsubstituted 
or substituted phenyl radical,
 
their enantiomers and diastereoisomers, their Z and E 

isomers, and the addition salts thereof with a pharmaceutically 
acceptable acid or base. 
Compounds according to claim 1 in which R
7
 represents 
hy
droxy,
 
their enantiomers and diastereoisomers, their Z and E 

isomers, and the addition salts thereof with a pharmaceutically 
acceptable acid or base. 
Compound according to claim 1 that is ethyl 1-hydroxy-3-((E)-3-
tert
-butyldimethylsilyloxy-7-phenylhept-1-en-1-yl)cyclohexane-1-acetate, 
and its enantiomers 

and diastereoisomers. 
Compound according to claim 1 that is ethyl 
(1S*,3S*)-1-hydroxy-3-((E)-3-
tert
-butyldimethylsilyloxy-7-phenyl-hept-1-en-1-yl)cyclohexane-1-acetate, 
and its 

enantiomers and diastereoisomers. 
Compound according to claim 1 that is ethyl 
(1S*,3S*)-1-hydroxy-3-((3R*S*,E)-3-hydroxy-7-phenyl-hept-1-en-1-yl)cyclohexane-1-acetate, 

and its enantiomers 
and diastereoisomers. 
Process for the preparation of compounds of 
formula (I), characterised in that:
 
a compound of formula (II):  

 

 
wherein R
3
, R
4
 and R
5
 are as defined for formula (I), is 
reacted with a product of formula (III): 


⊖
 B - R
2
 
wherein R
2
 and B are as defined for formula (I), to 
obtain the corresponding compound of formula (I
a
): 

 
wherein R
2
, R
3
, R
4
, R
5
 and B are as defined hereinbefore, 
which, if desired, may be: 


either subjected to the action of a product of 
formula (IV): 


R' 
⊕
 
wherein R' represents an alkyl radical, to obtain the 

compounds of formula (I
b
): 

 
wherein R
2
, R
3
, R
4
, R
5
, R' and B are as defined hereinbefore, 
or subjected to tosyl chloride, then to reduction with  
 

lithium aluminium hydride, to yield the compound of 
formula (I
c
): 

 
wherein R
2
, R
3
, R
4
, R
5
 and B are as defined hereinbefore,
 
it being possible for the compounds of formulae (I/a), 

(I/b) and (I/c) in which R
9
 represents a hydrogen atom 
and R
7
 represents a hydroxyl radical to be oxidised to 
obtain the compounds of formula (I/d): 


 
wherein R
1
, R
2
, R
4
, R
5
, R
8
 and B are as defined hereinbefore,
 
the compounds of formulae (I/a), (I/b), (I/c) and (I/d) 

representing the totality of the compounds of 
formula (I),
 
which compounds of formula (I) are, if desired, separated 

into their different enantiomers or diastereoisomers and, 
where appropriate, converted into their salts with a 

pharmaceutically acceptable acid or base. 
Process according to claim 8, characterised in that 
the separation of the diastereoisomers is effected by 

means of column chromatography.  
 
Process according to claim 8, characterised in that 
the separation of the diastereoisomers is effected by 

means of column chromatography and in that the group R
7
 
in the compounds of formula (I) according to claim 1 

represents a 
tert
-butyldimethylsilyloxy group. 
Pharmaceutical composition comprising as active 
ingredient at least one compound according to claim 1 in 

combination with one or more pharmaceutically acceptable 
excipients or carriers. 
Pharmaceutical composition according to claim 11 for 
use in the treatment and prevention of inflammatory 

disorders and pathological inflammatory conditions. 
Pharmaceutical composition according to claim 11 for 
use in the treatment and prevention of chronic or acute, 

articular, pulmonary, cutaneous or renal inflammation, 
and especially in the prevention and treatment of 

arthritis, rheumatoid polyarthritis, osteoarthrosis, 
psoriasis, allergic disorders, asthma, inflammatory 

disorders of the intestine, gastro-intestinal ulcers, 
ischaemia, atherosclerosis, respiratory distress and 

septic shock. 
</CLAIMS>
</TEXT>
</DOC>
